To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Inclusion Criteria: * Diagnosis of primary MF meeting the 2016 WHO criteria for overt PMF or secondary MF (PPV-MF or PET-MF) meeting the 2008 IWG-MRT criteria. * At least Intermediate 1 risk MF according to the DIPSS. * Prior treatment with ruxolitinib and/or fedratinib monotherapy * Currently receiving ruxolitinib or fedratinib monotherapy for PMF or secondary MF. * Splenomegaly defined as palpable spleen at least 5 cm below the left costal margin or volume ≥ 450 cm3 on imaging assessed during screening. * Allogeneic stem cell transplant not planned. * Platelet is greater than or equal to 50 × 109/L at screening. * Ability to comprehend and willingness to sign a written ICF for the study. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * Prior treatment with a JAK inhibitor other than ruxolitinib or fedratinib * Record of ≥ 10% myeloid blasts in the peripheral blood (on peripheral blood smear) or bone marrow prior to or at the time of screening * For participants on ruxolitinib or fedratinib, unable to be tapered from that treatment over the course of 14 days without corticosteroids, hydroxyurea, or other agents * Treatment with ruxolitinib, fedratinib or other MF-directed therapy (approved or investigational) within 2 weeks of Day 1 * Prior splenectomy or splenic irradiation within 6 months before receiving the first dose of itacitinib * Unable or unwilling to undergo serial MRI or CT scans for spleen volume measurement * Unable or unwilling t…